β-talasemia major
Indukcja farmakologiczna syntezy hemoglobiny płodowej
Leczenie hydroksymocznikiem (Hydroksykarbamid)
Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia. (opens new window)
Źródło: J Pediatr Hematol Oncol 2011;33(5):339-43.
Indeks: PubMed 21602718
DOI: 10.1097/MPH.0b013e31821b0770
https://www.ncbi.nlm.nih.gov/pubmed/21602718 (opens new window)
Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond? (opens new window)
Źródło: Ann Hematol 2013;92(3):289-99.
Indeks: PubMed 23318979
DOI: 10.1007/s00277-012-1671-3
https://www.ncbi.nlm.nih.gov/pubmed/23318979 (opens new window)
Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. (opens new window)
Źródło: Transfusion 2007;47(10):1830-6.
Indeks: PubMed 17880608
DOI: 10.1111/j.1537-2995.2007.01399.x
https://www.ncbi.nlm.nih.gov/pubmed/17880608 (opens new window)
Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease. (opens new window)
Źródło: Blood 1996;87(3):887-92.
Indeks: PubMed 8562958
https://www.ncbi.nlm.nih.gov/pubmed/8562958 (opens new window)
Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia. (opens new window)
Źródło: Iran J Blood Cancer 2009;1(4):147-50.
Indeks: IMEMR 107228
https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en (opens new window)
Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. (opens new window)
Źródło: Hematology 2015;20(1):53-7.
Indeks: PubMed 24717020
DOI: 10.1179/1607845414Y.0000000168
https://www.ncbi.nlm.nih.gov/pubmed/24717020 (opens new window)
Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. (opens new window)
Źródło: Int J Hematol 2012;95(1):51-6.
Indeks: PubMed 22180324
DOI: 10.1007/s12185-011-0985-6
https://www.ncbi.nlm.nih.gov/pubmed/22180324 (opens new window)
Report on Patients with Non Transfusion-Dependent β-Thalassemia Major Being Treated with Hydroxyurea Attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013. (opens new window)
Źródło: Hemoglobin 2014;38(2):115-8.
Indeks: PubMed 24471558
DOI: 10.3109/03630269.2013.869229
https://www.ncbi.nlm.nih.gov/pubmed/24471558 (opens new window)
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. (opens new window)
Źródło: Blood 2013;121(12):2199-212.
Indeks: PubMed 23315167
DOI: 10.1182/blood-2012-10-408021
https://www.ncbi.nlm.nih.gov/pubmed/23315167 (opens new window)
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. (opens new window)
Źródło: Sci Rep. 2022;12(1):2752.
Indeks: PubMed 35177777
DOI: 10.1038/s41598-022-06774-8
https://pubmed.ncbi.nlm.nih.gov/35177777/ (opens new window)
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. (opens new window)
Źródło: Haematologica 2004;89(10):1172-8.
Indeks: PubMed 15477200
https://www.ncbi.nlm.nih.gov/pubmed/15477200 (opens new window)
Hydroxyurea therapy in 49 patients with major beta-thalassemia. (opens new window)
Źródło: Arch Iran Med 2009;12(3):295-7.
Indeks: PubMed 19400608
https://www.ncbi.nlm.nih.gov/pubmed/19400608 (opens new window)
Rekombinowana erytropoetyna (sama lub w połączeniu z innymi środkami)
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (opens new window)
Źródło: Eur J Haematol 1996;56(5):326-8.
Indeks: PubMed 8641410
https://www.ncbi.nlm.nih.gov/pubmed/8641410 (opens new window)
Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy. (opens new window)
Źródło: J Matern Fetal Med 1999;8(1):1-7.
Indeks: PubMed 10052837
DOI: 10.1002/(SICI)1520-6661(199901/02)8:1<1::AID-MFM1>3.0.CO;2-O
https://www.ncbi.nlm.nih.gov/pubmed/10052837 (opens new window)
Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (opens new window)
Źródło: Acta Haematol 2004;111(4):189-95.
Indeks: PubMed 15153710
DOI: 10.1159/000077551
https://www.ncbi.nlm.nih.gov/pubmed/15153710 (opens new window)
Recombinant human erythropoietin therapy in a transfusion-dependent β-thalassemia major patient. (opens new window)
Źródło: Ann Hematol 2001;80(8):492-5.
Indeks: PubMed 11563599
https://www.ncbi.nlm.nih.gov/pubmed/11563599 (opens new window)
Fetal globin induction--can it cure beta thalassemia? (opens new window)
Źródło: Hematology Am Soc Hematol Educ Program 2005:38-44.
Indeks: PubMed 16304357
DOI: 10.1182/asheducation-2005.1.38
https://www.ncbi.nlm.nih.gov/pubmed/16304357 (opens new window)